CytomX Therapeutics (CTMX) Free Cash Flow (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | CytomX Therapeutics | 638.18 Mn | 291.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.98% |
| Dec 31, 2025 | -52.03% |
| Sep 30, 2025 | 2.28% |
| Jun 30, 2025 | 25.43% |
| Mar 31, 2025 | -7.50% |
| Dec 31, 2024 | 5.12% |
| Sep 30, 2024 | -5.61% |
| Jun 30, 2024 | 24.90% |
| Mar 31, 2024 | -17.68% |
| Dec 31, 2023 | -21.79% |
| Sep 30, 2023 | 28.97% |
| Jun 30, 2023 | -376.26% |
| Mar 31, 2023 | 5,749.69% |
| Dec 31, 2022 | 100.46% |
| Sep 30, 2022 | 1.14% |
| Jun 30, 2022 | 17.60% |
| Mar 31, 2022 | -33.76% |
| Dec 31, 2021 | -1.38% |
| Sep 30, 2021 | -13.71% |
| Jun 30, 2021 | 11.81% |
| Mar 31, 2021 | -58.14% |
| Dec 31, 2020 | 17.76% |
| Sep 30, 2020 | -124.49% |
| Jun 30, 2020 | 291.12% |
| Mar 31, 2020 | -87.31% |
| Dec 31, 2019 | -5.49% |
| Sep 30, 2019 | 45.58% |
| Jun 30, 2019 | -15.58% |
| Mar 31, 2019 | -50.79% |
| Dec 31, 2018 | -310.54% |
| Sep 30, 2018 | 75.98% |
| Jun 30, 2018 | -78.90% |
| Mar 31, 2018 | -166.89% |
| Dec 31, 2017 | 496.31% |
| Sep 30, 2017 | -103.37% |
| Jun 30, 2017 | 991.27% |
| Mar 31, 2017 | -10,513.19% |
| Dec 31, 2016 | 98.65% |
| Sep 30, 2016 | -188.02% |
| Jun 30, 2016 | 361.97% |
| Mar 31, 2016 | 14.44% |
| Dec 31, 2015 | 15.65% |
| Sep 30, 2015 | -17.73% |
| Jun 30, 2015 | -22.78% |
| Mar 31, 2015 | -11.10% |